CARLSBAD, Calif., and BILBAO, Spain — Artis BioSolutions has launched a new Genetic Medicines Center of Excellence in Bilbao, expanding its capabilities in mRNA, lipid nanoparticles and GMP drug manufacturing.
The new center brings together synthetic DNA, mRNA drug substance manufacturing, lipid nanoparticle formulation and manufacturing, and GMP drug product manufacturing within a single organization. Artis said the integrated platform is designed to help biotechnology companies move genetic medicine programs from early development through clinical trials and commercial production.
“The expansion into mRNA and LNP development services and technologies within our new Genetic Medicines Center of Excellence represents a defining milestone for Artis,” said Brian Neel, Chief Executive Officer of Artis BioSolutions. “The future of genetic medicines demands new innovations and integrated partners that can seamlessly support the advancement of new therapeutic targets from development through commercialization.”
Neel said combining synthetic DNA, mRNA, LNP technologies and GMP manufacturing could help customers reduce development complexity, costs and technology-transfer requirements while accelerating new therapies to market.
Genetic medicine developers often rely on multiple suppliers for DNA starting materials, RNA production, delivery technology, formulation, analytics and drug product manufacturing. Artis said consolidating those services is intended to create a more coordinated development process and reduce operational risk.
“The genetic medicines landscape has evolved rapidly, but development remains significantly fragmented,” said Peter Stolba, Chief Business Officer of Artis BioSolutions. “Companies are often required to coordinate across multiple suppliers, adding unnecessary time, cost, and risk.”
Stolba said the Bilbao center, combined with the company’s synthetic DNA platform, will allow Artis to support customers from starting materials through commercialization.
The Bilbao facility expands Artis BioSolutions’ global manufacturing footprint, which also includes Boston BioSolutions in Watertown, Massachusetts.
The company said its network provides process development, technology transfer, clinical manufacturing and commercial-scale GMP manufacturing capabilities across multiple genetic medicine modalities.
